This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Stocks to Watch: ICE, NYSE, Bed Bath, RIM

NEW YORK -- NYSE Euronext (NYX), the operator of the New York Stock Exchange, is in talks to sell itself to rival IntercontinentalExchange (ICE), according to reports.

People close to the discussions told The Wall Street Journal an announcement could come as early as Thursday.

Under a deal, ICE would value NYSE at $33 a share, a 37% premium to its closing price on Wednesday, according to a report from CNBC.

NYSE closed Wednesday at $24.05 and soared more than 20% in after-hours trading.


Bed Bath & Beyond (BBBY) on Wednesday issued forecasts for the fourth quarter and fiscal year that were below analysts' views.

The retailer said it expects fourth-quarter earnings of $1.60 to $1.67 a share, and fiscal-year earnings of $4.48 to $4.54 a share.

Analysts are calling for fourth-quarter earnings of $1.75 a share, and 2012 earnings of $4.62 a share.

Bed Bath & Beyond's board also authorized a new $2.5 billion stock buyback program.

5 Retail Sector Bargains to Buy Before 2013


Jabil Circuit (JBL) posted fiscal first-quarter earnings on Wednesday that topped Wall Street estimates.

Adjusted earnings for the first quarter were 61 cents a share; analysts forecast profit of 56 cents a share.

Jabil said sales in the quarter rose to $4.64 billion from $4.33 billion a year earlier. Analysts were expecting sales of $4.41 billion.

Stephen Gillett Leaves Sinking-Ship Best Buy for Symantec


Research In Motion (RIMM), the BlackBerry maker, is expected by analysts on Thursday to post a fiscal third-quarter loss of 35 cents a share.

RIM, which has steadily been losing market share in the U.S., is banking on reversing its fortunes with BlackBerry 10, the new operating system that will be unveiled at the end of next month.


An experimental therapy from Amicus Therapeutics (FOLD) and GlaxoSmithKline (GSK) failed to improve kidney response in Fabry disease patients compared to placebo in a late-stage study, the companies disclosed late Wednesday.

Amicus shares closed Wednesday at $5.77 but fell 55% to $2.60 in after-hours trading.

Amicus Fabry Drug Fails Pivotal Trial


Analysts expect ConAgra Foods (CAG) on Thursday to report fiscal second-quarter earnings of 55 cents a share on revenue of $3.69 billion.


Discover Financial Services (DFS) is expected by Wall Street to post fourth-quarter earnings Thursday of $1.11 a share.


-- Written by Joseph Woelfel



>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,987.51 -61.49 -0.36%
S&P 500 1,985.54 -11.91 -0.60%
NASDAQ 4,567.5980 -24.2080 -0.53%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs